IP Library Granted Patent US 8,114,960
Granted Patent B2
US 8,114,960 · App. 12/825,210 · Granted Feb 14, 2012

Heterologous expression of Neisserial proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,960
App. No.
12/825,210
Granted
Feb 14, 2012
Kind
B2
Abstract

Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae . These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.

Claims (13)

1. An immunogenic protein comprising a sequence having greater than 90% sequence identity to a sequence represented by SEQ ID NO: 84, in which at least one domain in the protein is deleted, wherein the at least one domain is selected from the group comprising amino acids 1-24 of SEQ ID NO: 84, amino acids 1-69 of SEQ ID NO: 84, amino acids 1-106 of SEQ ID NO: 84, amino acids 1-202 of SEQ ID NO: 84, amino acids 203-288 of SEQ ID NO: 84, and amino acids 289-488 of SEQ ID NO: 84, and wherein the protein has at least one domain.

2. The immunogenic protein of claim 1 , in which the N-terminal domain of the protein is mutated.

3. The immunogenic protein of claim 1 , wherein the protein includes a C-terminal His-tag.

4. The immunogenic protein of claim 1 , wherein the protein includes an N-terminal GST.

5. The immunogenic protein of claim 1 , wherein the immunogenic protein is at the N-terminus of a hybrid protein.

6. The immunogenic protein claim 1 , wherein the protein comprises a sequence having greater than 95% sequence identity to a sequence represented by SEQ ID NO: 84.

7. A method for producing an immunogenic protein comprising expressing in a heterologous host a protein comprising the immunogenic protein of claim 1 ; and purifying the protein.

8. The method of claim 7 , in which the N-terminal domain of the protein is mutated.

9. The method of claim 7 , in which the heterologous host is an E. coli host.

10. The method of claim 7 , wherein the protein includes a C-terminal His-tag.

11. The method of claim 7 , wherein the protein includes an N-terminal GST.

12. The method of claim 7 , wherein the immunogenic protein is at the N-terminus of a hybrid protein.

13. The method of claim 7 , wherein the protein comprises a sequence having greater than 95% sequence identity to a sequence represented by SEQ ID NO: 84.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2015
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 035231/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2015
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 035219/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2011
From: NOVARTIS VACCINES AND DIAGNOSTICS SRL
To: NOVARTIS AG
Reel/Frame 027055/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2010
From: ARICO, MARIA BEATRICE; COMANDUCCI, MAURIZIO; GALEOTTI, CESIRA; MASIGNANI, VEGA; GIULIANI, MARZIA MONICA; PIZZA, MARIAGRAZIA
To: CHIRON SRL
Reel/Frame 025346/0705 →
CHANGE OF NAME Recorded Nov 10, 2010
From: CHIRON SRL
To: NOVARTIS VACCINES AND DIAGNOSTICS SRL
Reel/Frame 025346/0718 →